Evidence map›Paper›PMID 41328879›Full record

ArticlePsychogeriatrics : the official journal of the Japanese Psychogeriatric Society2026

Impulse Dyscontrol Symptoms Are Related to Amyloid Beta in Patients With Subjective Cognitive Decline and Mild Cognitive Impairment.

Ana Luiza Gonçalves Rochetti, Isadora Cristina Ribeiro, Lucas Luchesi Barnes, Liara Rizzi, Italo Karmann Aventurato, Brenda Costa Gonçalves, Marjorie Cristina Rocha da Silva, Marcio Luiz Figueredo Balthazar

Abstract read
In one paragraph

Article in Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ana Luiza Gonçalves RochettiSchool of Medical Sciences, UNICAMP/SP, Campinas, Brazil.
Isadora Cristina RibeiroSchool of Medical Sciences, UNICAMP/SP, Campinas, Brazil.
Lucas Luchesi BarnesSchool of Medical Sciences, UNICAMP/SP, Campinas, Brazil.ORCID https://orcid.org/0000-0003-1037-6047
Liara RizziSchool of Medical Sciences, UNICAMP/SP, Campinas, Brazil.
Italo Karmann AventuratoSchool of Medical Sciences, UNICAMP/SP, Campinas, Brazil.
Brenda Costa GonçalvesSchool of Medical Sciences, UNICAMP/SP, Campinas, Brazil.
Marjorie Cristina Rocha da SilvaSchool of Medical Sciences, UNICAMP/SP, Campinas, Brazil.
Marcio Luiz Figueredo BalthazarSchool of Medical Sciences, UNICAMP/SP, Campinas, Brazil.

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 18/15571-7
6 · The paper itself

Abstract

introductionThe relationship between neuropsychiatric symptoms (NPSs) and Alzheimer's disease (AD) pathophysiology, considering cerebrospinal fluid (CSF) biomarkers, is still not clarified and the available results in the literature are contradictory especially when it comes to the prodromic stages of AD. Clarifying the role of the AD biomarkers in the development of NPS in subjective cognitive decline (SCD) and mild cognitive impairment (MCI) is relevant and can be useful for planning longitudinal interventions in the AD continuum. The present work studies the correlation between NPSs and AD CSF biomarkers in SCD and MCI Brazilian subjects.

methodsThis is a transversal study designed to evaluate the relationship between NPS and CSF AD biomarkers in SCD and MCI individuals. Voluntary participants were recruited through a virtually announced formulary. The inclusion criteria were age 55 years or older, of both sexes, without distinction of ethnicity or socioeconomic status, the presence of cognitive complaints, and that were willing to participate in all research procedures. Exclusion criteria for all subjects included clinical dementia, other neurological or psychiatric diseases, traumatic brain injury that resulted in a loss of consciousness, drug or alcohol addiction, prior chronic exposure to neurotoxic substances, Fazekas scale ≥ 2, and a score on the Montreal Cognitive Assessment (MoCA) less than 17 points. All participants had Pfeffer's Functional Activities Questionnaire < 5 and underwent medical and neuropsychological evaluation.

resultsSeventy-one patients were included between 2019 and 2022, 54 with MCI and 17 with SCD. A significant correlation (p: 0.006) was observed between MBI-C C domain and the concentrations of CSF amyloid-beta peptide.

conclusionThe study identified a significant correlation between domain C of the MBI-C and CSF beta-amyloid peptide analysing Brazilian patients with SCD and MCI. The results reinforce the hypothesis of the relationship between impulsivity symptoms and amyloid pathology. Further studies involving the correlations between MBI and neuropsychiatric symptoms with AD CSF biomarkers are necessary.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesCognitive DysfunctionDisruptive, Impulse Control, and Conduct DisordersAgedBiomarkersBrazilCross-Sectional StudiesFemaleHumansMaleMiddle AgedNeuropsychological TestsAmyloid beta-PeptidesBiomarkers

Identifiers

PMID41328879
PMCPMC12670987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.